Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Biopsy 15Flow Cytometry 14Cyclosporins 14Alemtuzumab 14thymoglobulin 13venetoclax 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × STA 9090 × Myeloid × Clear all
NCT00858572 2014-09-18

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Synta Pharmaceuticals Corp.

Phase 1 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡